William T. Hendriks, Curtis R. Warren, Chad A. Cowan  Cell Stem Cell 

Slides:



Advertisements
Similar presentations
Lecture-7 Genome editing CRISPR
Advertisements

Molecular Therapy - Nucleic Acids
Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1
Volume 8, Issue 3, Pages (March 2017)
Pluripotent stem cell based gene therapy for hematological diseases
Expanding the Biologist’s Toolkit with CRISPR-Cas9
CRISPR-Cas Systems: Prokaryotes Upgrade to Adaptive Immunity
Rewiring Cas9 to Target New PAM Sequences
Figure 2 Use of CRISPR/Cas9 for genome editing
CRISPR/Cas9-mediated genome editing of PML in human cell lines.
Molecular Therapy - Nucleic Acids
CRISPR CRISPRs (clustered regularly interspaced short palindromic repeats) are repetitive nucleotide sequences followed by a short spacer DNA segments.
Astrid Breitbart, Charles E. Murry  Cell Stem Cell 
Gaelen T. Hess, Josh Tycko, David Yao, Michael C. Bassik 
CRISPR-Cas Systems: Prokaryotes Upgrade to Adaptive Immunity
Volume 62, Issue 1, Pages (April 2016)
Volume 9, Issue 4, Pages (October 2017)
Research Techniques Made Simple: The Application of CRISPR-Cas9 and Genome Editing in Investigative Dermatology  Joan Ramon Guitart, Jodi L. Johnson,
Mouse Genome Engineering via CRISPR-Cas9 for Study of Immune Function
Molecular Therapy - Nucleic Acids
Astrid Breitbart, Charles E. Murry  Cell Stem Cell 
Molecular Therapy - Nucleic Acids
Volume 17, Issue 2, Pages (August 2015)
Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR
CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles
Therapeutic editing of hepatocyte genome in vivo
USH2A Gene Editing Using the CRISPR System
CRISPR genome-editing: A medical revolution
Volume 164, Issue 1, Pages (January 2016)
Volume 8, Issue 3, Pages (March 2017)
Andrew R. Bassett, Charlotte Tibbit, Chris P. Ponting, Ji-Long Liu 
Xiaoyu Chen, Jin Liu, Josephine M. Janssen, Manuel A.F.V. Gonçalves 
Volume 154, Issue 6, Pages (September 2013)
Simultaneous Reprogramming and Gene Correction of Patient Fibroblasts
Zinc Fingers, TAL Effectors, or Cas9-Based DNA Binding Proteins: What’s Best for Targeting Desired Genome Loci?  Annett Strauβ, Thomas Lahaye  Molecular.
Volume 153, Issue 4, Pages (May 2013)
Current Progress in Therapeutic Gene Editing for Monogenic Diseases
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Advances in Industrial Biotechnology Using CRISPR-Cas Systems
Volume 69, Issue 1, Pages e3 (January 2018)
Targeted Myostatin Gene Editing in Multiple Mammalian Species Directed by a Single Pair of TALE Nucleases  Li Xu, Piming Zhao, Andrew Mariano, Renzhi.
Volume 10, Issue 2, Pages (February 2018)
Volume 11, Issue 6, Pages (May 2015)
Volume 25, Issue 1, Pages (January 2017)
Molecular Therapy - Methods & Clinical Development
A CRISPR Approach to Gene Targeting
Volume 153, Issue 4, Pages (May 2013)
Ignazio Maggio, Manuel A.F.V. Gonçalves  Trends in Biotechnology 
Volume 25, Issue 2, Pages (February 2017)
Molecular Therapy - Nucleic Acids
Volume 23, Issue 3, Pages (March 2015)
Tagging of the endogenous Py03652 gene with the gfp gene in Plasmodium yoelii. Tagging of the endogenous Py03652 gene with the gfp gene in Plasmodium yoelii.
Volume 17, Issue 5, Pages (October 2016)
Volume 17, Issue 2, Pages (August 2015)
Gene editing: modifying a gene that was already there
Volume 15, Issue 2, Pages (August 2014)
Gene editing by CRISPR/Cas9 for gene inactivation and targeted sequence replacement. Gene editing by CRISPR/Cas9 for gene inactivation and targeted sequence.
Volume 16, Issue 4, Pages (April 2015)
Volume 16, Issue 2, Pages (February 2015)
CRISPR/Cas9: Transcending the Reality of Genome Editing
Volume 5, Issue 5, Pages (November 2015)
Volume 13, Issue 3, Pages (October 2015)
Chemical Biology Approaches to Genome Editing: Understanding, Controlling, and Delivering Programmable Nucleases  Johnny H. Hu, Kevin M. Davis, David R.
Volume 26, Issue 11, Pages (November 2018)
Off-target Effects in CRISPR/Cas9-mediated Genome Engineering
Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off- target Effects in Genome Editing  Ciaran M Lee, Thomas J Cradick,
New Tools for Genome Modification in Human Embryonic Stem Cells
Volume 10, Issue 2, Pages (February 2018)
Presentation transcript:

Genome Editing in Human Pluripotent Stem Cells: Approaches, Pitfalls, and Solutions  William T. Hendriks, Curtis R. Warren, Chad A. Cowan  Cell Stem Cell  Volume 18, Issue 1, Pages 53-65 (January 2016) DOI: 10.1016/j.stem.2015.12.002 Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 1 Human Pluripotent Stem Cell Gene-Editing Workflow (1) In silico design of the TALE array or CRISPR guide RNA. (2) Cloning and construction of nuclease and guide RNA vectors, either as DNA, mRNA, or protein (3) for transfection or transduction of single-cell hPSCs is shown. (4) After transfection or transduction, gene-targeted cells can either be selected with FACS if the transfected vectors contain a fluorescent reporter or antibiotics if there is a selection marker present in the nuclease vector. (5) One to two weeks after enrichment of targeted cells, hPSC colonies (6) are picked and expanded for genomic DNA analysis and for targeted clone recovery and expansion if genome editing was successful. Cell Stem Cell 2016 18, 53-65DOI: (10.1016/j.stem.2015.12.002) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 2 Custom-Engineered Nucleases TALEN and CRISPR/Cas9 (A) Schematic showing TALE DNA-binding array in this example comprising 15 RVDs, each binding their cognate nucleotide in the target sequence. The TALE-binding arrays each are fused to a FokI monomer. In order for FokI dimerization and DSB to occur, there needs to be a DNA spacing sequence of 15–18 nucleotides between the 5′ and 3′ TALE-binding array. The four canonical TALE RVDs are shown as well. (B) The CRISPR/Cas9 system consists of a guide RNA that contains a 20-nucleotide-long target DNA-matching sequence immediately upstream of a protospacer adjacent motif (PAM) that for S. pyogenes Cas9 is NGG. Without this PAM site, the Cas9 nuclease is unable to form a complex with the guide RNA and introduce a double-stranded break. (C) So-called Cas9 nickase (Cas9D10A) is an engineered wild-type Cas9 that creates a DNA nick instead of a DSB. Co-expression of two sgRNAs in each other’s vicinity with Cas9 nickase will create DNA nicks, essentially forming a DSB. The dual nickase approach as shown in this schematic has been shown to increase specificity of gene editing (see text for details). Different Cas9 orthologs, each with their own PAM requirements, have been used for gene editing. Cell Stem Cell 2016 18, 53-65DOI: (10.1016/j.stem.2015.12.002) Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 3 Genome-Edited hPSC Selection and Genotyping (A) Example of FACS enrichment of transfected hPSCs. Left panel shows mock electroporated hPSCs with no GFP-positive cells, whereas the right panel shows hPSCs electroporated with sgRNA and Cas9-GFP. (B) NHEJ-mediated indel formation in FACS-enriched hPSCs creates heterozygous and homozygous frame shift, causing mutations resulting in gene knockout. Alternatively, co-expression of an ssODN containing a SNP and a restriction enzyme site, with Cas9-GFP and a sgRNA, results in HDR-mediated introduction of the SNP in the hPSC genome. (C) Upon PCR screening of FACS-enriched hPSCs, Sanger sequencing of positive clones confirms and identifies genotype. Shown are potential outcomes after gene editing with Cas9-GFP and a sgRNA. Cell Stem Cell 2016 18, 53-65DOI: (10.1016/j.stem.2015.12.002) Copyright © 2016 Elsevier Inc. Terms and Conditions